Abstracts tagged "Lupus"

Abstract Number: 1666 • 2018 ACR/ARHP Annual Meeting
The Use of Patient-Reported Outcome Measures to Assess Clinical Features of Fibromyalgia in SLE
Jennifer Rogers¹, Amanda M. Eudy², Lisa Criscione-Schreiber², David Pisetsky³, Kai Sun⁴, Jay Doss⁴ and Megan E. B. Clowse², ¹Medicine, Divison of Rheumatology, Duke University, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ³Department of Medicine, Duke University, Durham, NC, ⁴Division of Rheumatology & Immunology, Duke University, Durham, NC
Background/Purpose: Patient-reported outcome measures (PROs) in SLE can capture patient specific information and the patient perspective, but clinical use can be challenging due to confounding…
Abstract Number: 2089 • 2018 ACR/ARHP Annual Meeting
The Differential Impact of the Abrogation of the Costimulatory Molecule CD137 Ligand on Renal and Cerebral Manifestations in C57BL/6.Faslpr-/- mice
Anselm Mak¹, Bhushan Dharmadhikari², Lik Wei Wong², Saji Kumar Sreedharan² and Herbert Schwarz², ¹Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Background/Purpose: Costimulatory molecules which mediate cross-talks between leukocytes, have been identified to play a pathogenetic pivotal role in systemic lupus erythematosus (SLE). Abrogation of the…
Abstract Number: 2675 • 2018 ACR/ARHP Annual Meeting
Age-Related Metabolic Changes Underlie Pro-Inflammatory Lineage Specification and Contribute to Therapeutic Responsiveness to Mechanistic Target of Rapamycin Blockade in SLE
Zhi-Wei Lai¹, Ryan Kelly² and Andras Perl¹, ¹Medicine, SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY
Background/Purpose: Systemic lupus erythematosus (SLE) patients exhibit T-cell dysfunction which can be reversed by blockade of the mechanistic target of rapamycin (mTOR) with therapeutic efficacy…
Abstract Number: 503 • 2017 ACR/ARHP Annual Meeting
BMS-986195 Is a Highly Selective and Rapidly Acting Covalent Inhibitor of Bruton’s Tyrosine Kinase with Robust Efficacy at Low Doses in Preclinical Models of RA and Lupus Nephritis
JR Burke, KM Gillooly, MA Pattoli, L Cheng, S Skala, EM Heimrich, TL Taylor, C Pulicicchio, DW Kukral, T Petrone, IM Catlett, N Zheng, W Li, SH Watterson and JA Tino, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK), a member of the Tec family of non-receptor tyrosine kinases essential in…
Abstract Number: 1273 • 2017 ACR/ARHP Annual Meeting
Patient Health Questionnaire-9 Utilization for the Detection of Depression in Adolescents and Young Adults with Lupus Nephritis
Peter Yorgin¹, Eleanor Lazarow² and Robert Sheets³, ¹Pediatrics, Rady Children's Hospital/University of California San Diego, San Diego, CA, ²Social Work, Rady Children's Hospital, San Diego, CA, ³Pediatrics, Rady Children's Hospital/UCSD, San Diego, CA
Background/Purpose: The PHQ-9 is a self-administered depression screening questionnaire. Patients with a PHQ-9 score of 0-4 have no depression, 5-9, mild; 10-14, moderate; 15-19, moderately severe;…
Abstract Number: 1832 • 2017 ACR/ARHP Annual Meeting
Gut Dysbiosis Contributes to Autoimmune Pathogenesis in Lupus-Prone Mice
Seung Chul Choi¹, Josephine Brown¹, Mansour Mohamadzadeh², Byron Croker¹ and Laurence Morel³, ¹Pathology, University of Florida, Gainesville, FL, ²Infectious Diseases & Pathology, University of Florida, Gainesville, FL, ³Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL
Background/Purpose: Multiple studies have demonstrated that commensal bacteria play an immunoregulatory role and that gut dysbiosis is associated with inflammatory diseases. This study was conducted…
Abstract Number: 2618 • 2017 ACR/ARHP Annual Meeting
Why Aren’t All Patients with SLE Taking Hydroxychloroquine? A Retrospective Chart Review
Caroline H. Siegel¹, Jennifer M. Grossman¹, John Fitzgerald¹, Bevra H. Hahn^1,2, Lori Sahakian¹, Eloise Olmos² and Maureen A. McMahon¹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Although previous SLE treatment guidelines recommended judicious use of antimalarials, there is a growing body of evidence demonstrating that HCQ prevents flares, protects against…
Abstract Number: 667 • 2017 ACR/ARHP Annual Meeting
Urinary Metabolomic Fingerprint As Diagnostic Biomarker for Clinical Significant Lupus Nephritis
David Herrera Van Oostdam¹, Rogelio Flores Ramirez², Maribel Rodriguez Aguilar², Mauricio Pierdant Pérez³, Carlos Abud-Mendoza⁴, David Martínez-Galla⁵ and Marco Ulises Martinez-Martinez⁶, ¹Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ²2. Coordinación para la Innovación y Aplicación de la Ciencia y la Tecnología, San Luis Potosí, San Luis Potosi, Mexico, ³Universidad Autónoma de San Luis Potosí, San Luis Potosi, Mexico, ⁴Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, ⁵Pathology, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, ⁶Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico
-Background/Purpose: Lupus nephritis (LN) represents the main prognostic factor in systemic lupus erythematosus (LES) [1]. The clinical significant classes of LN –due to the need…
Abstract Number: 1291 • 2017 ACR/ARHP Annual Meeting
Preterm Delivery Phenotypes in SLE Pregnancies
Julia F Simard¹, Yashaar Chaichian², Marios Rossides³, Anna-Karin Wikstrom⁴, Gary M. Shaw⁵ and Maurice Druzin⁶, ¹Medicine, Division of Immunology & Rheumatology, Stanford School of Medicine, Stanford, CA, ²Medicine, Immunology & Rheumatology Division, Stanford School of Medicine, Stanford, CA, ³Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ⁵Pediatrics, Division of Neonatology and Developmental Medicine, Stanford School of Medicine, Stanford, CA, ⁶Obstetrics & Gynecology, Stanford School of Medicine, Stanford, CA
Background/Purpose: Women with systemic lupus erythematosus (SLE) are at greater risk of preterm delivery compared to women without lupus. A significant proportion of SLE pregnancies…
Abstract Number: 1833 • 2017 ACR/ARHP Annual Meeting
iRhom2 Deficiency Protects Fcgr2b-/- Lupus-Prone Mice from Kidney Damage By Modulating ADAM17-Dependent Shedding of TNF-α and EGFR Ligand
Xiaoping Qing¹, Yurii Chinenov², Patricia M. Redecha³, Michael Madaio⁴, Priya Issuree⁵, David McIlwain⁶, Tak Mak⁷, Carl Blobel⁵ and Jane E. Salmon⁸, ¹Program in Inflammation and Autoimmunity, Hospital for Special Surgery, New York, NY, ²Arthritis & Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, ³Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY, ⁴Medicine, Medical College of Georgia, Augusta, GA, ⁵Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, ⁶Department of Microbiology and Immunology, Stanford University, Stanford, CA, ⁷Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Center, Toronto, ON, Canada, ⁸Medicine/Rheumatology, Hospital of Special Surgery, New York, NY
Background/Purpose: A disintegrin and metalloprotease 17 (ADAM17) controls ecto-domain shedding of TNFα and epithelial-growth factor ligands (EGFR) such as heparin-binding EGF (HB-EGF). TNFa and HB-EGF…
Abstract Number: 2632 • 2017 ACR/ARHP Annual Meeting
The Southern California Lupus Registry: I. Baseline Characteristics of Patients with Systemic Lupus Erythematosus in an Uncharted Territory
Joshua Liu¹, Kathleen Teves², Van La², Arlene Bravo³, Sheila Lezcano⁴, Talha Khawar⁴, Ebrahim Sadeghi⁴, Cong-Bin Wang⁵, Karina Torralba⁶, Howard Yang⁵ and Vaneet K. Sandhu⁷, ¹Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA, ²Internal Medicine, University of California, Riverside, Riverside, CA, ³Internal Medicine, Loma Linda University, Loma Linda, CA, ⁴Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, ⁵Loma Linda University Medical Center, Loma Linda, CA, ⁶Internal Medicine/Rheumatology, Loma Linda University, Loma Linda, CA, ⁷Division of Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: The Southern California Lupus Registry (SCOLR) is a population-based, longitudinal, multi-ethnic cohort of subjects with SLE directed toward studying health and healthcare disparities in…
Abstract Number: 677 • 2017 ACR/ARHP Annual Meeting
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts the Development of Organ Damage over 5 Years in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Helena Enocsson¹, Lina Wirestam¹, Jonas Wetterö¹, Thomas Skogh¹, Ian N. Bruce^2,3 and Christopher Sjöwall⁴, ¹Rheumatology, Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, Linköping, Sweden, ²Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ³NIHR Manchester Musculoskeletal Biomedical Research Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁴Department of Clinical and Experimental Medicine, Linköping University, Sweden, Linköping, Sweden
Background/Purpose: The urokinase plasminogen activator receptor (uPAR) is expressed on various cell types and plays important roles in proteolysis, migration and adhesion. Receptor shedding yields…
Abstract Number: 1294 • 2017 ACR/ARHP Annual Meeting
Time to Pregnancy in Women with Systemic Lupus Erythematosus
Meriem El bakali¹, Sasha Bernatsky², Christian A. Pineau³ and Evelyne Vinet⁴, ¹Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ²Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴Divisions of Rheymatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Women diagnosed with systemic lupus erythematosus (SLE) during the reproductive period have fewer children than unaffected women. Multiple disease-related factors might influence family size…
Abstract Number: 1839 • 2017 ACR/ARHP Annual Meeting
Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials
Michal Abrahamowicz¹, John M. Esdaile², Rosalind Ramsey-Goldman³, Lee S. Simon⁴, Vibeke Strand⁵ and Peter E. Lipsky⁶, ¹Departmernt of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³FSM, Northwestern University, Chicago, IL, ⁴SDG LLC Consulting, West Newton, MA, ⁵Stanford University, Palo Alto, CA, ⁶AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Randomized controlled trials (RCTs) of new SLE treatments are hampered by the lack of effective outcome measures that are responsive to change and clinically…
Abstract Number: 2636 • 2017 ACR/ARHP Annual Meeting
EZH2 Modulates the DNA Methylome and Controls T Cell Adhesion through Junctional Adhesion Molecule-a in Lupus Patients
Pei-Suen Tsou¹, Patrick Coit¹, Nathan Kilian² and Amr H Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: EZH2 is an epigenetic regulator that trimethylates lysine 27 of histone 3 (H3K27me3) and modulates DNA methylation patterns. We have previously suggested that EZH2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].